中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
22期
8-10
,共3页
高脂血症%高尿酸血症%阿托伐他汀%别嘌醇%代谢综合征
高脂血癥%高尿痠血癥%阿託伐他汀%彆嘌醇%代謝綜閤徵
고지혈증%고뇨산혈증%아탁벌타정%별표순%대사종합정
Hyperlipemia%Hyperuricemia%Atorvastatin%Allopurinol%Metabolic syndrome
目的 观察阿托伐他汀钙联合不同剂量别嘌醇对高脂血症患者血尿酸(UA)及血脂水平的影响.方法 90例高脂血症伴高尿酸血症患者随机分为三组:A组(常规剂量别嘌醇治疗)、B组(小剂量别嘌醇+阿托伐他汀治疗)及C组(常规剂量别嘌醇+阿托伐他汀治疗), 各30例.治疗4周后比较三组患者治疗前后的血尿酸和血脂的变化及不良反应.结果 治疗4周后三组血尿酸均显著下降, 其中B、C组均比A组下降更明显, 差异有统计学意义(P<0.05).A组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)轻度下降, 与治疗前比较, 差异有统计学意义(P<0.05), B、C组TC、TG、LDL-C显著下降, 与治疗前比较, 差异有统计学意义(P<0.05).治疗4周后, B组与C组血脂及血尿酸指标相比较, 差异无统计学意义(P>0.05).结论 阿托伐他汀钙联合别嘌醇能更有效改善高脂血症患者的血脂水平, 同时具有降低尿酸作用, 而联合小剂量别嘌醇即可达到良好治疗效果.
目的 觀察阿託伐他汀鈣聯閤不同劑量彆嘌醇對高脂血癥患者血尿痠(UA)及血脂水平的影響.方法 90例高脂血癥伴高尿痠血癥患者隨機分為三組:A組(常規劑量彆嘌醇治療)、B組(小劑量彆嘌醇+阿託伐他汀治療)及C組(常規劑量彆嘌醇+阿託伐他汀治療), 各30例.治療4週後比較三組患者治療前後的血尿痠和血脂的變化及不良反應.結果 治療4週後三組血尿痠均顯著下降, 其中B、C組均比A組下降更明顯, 差異有統計學意義(P<0.05).A組總膽固醇(TC)、甘油三酯(TG)、低密度脂蛋白膽固醇(LDL-C)輕度下降, 與治療前比較, 差異有統計學意義(P<0.05), B、C組TC、TG、LDL-C顯著下降, 與治療前比較, 差異有統計學意義(P<0.05).治療4週後, B組與C組血脂及血尿痠指標相比較, 差異無統計學意義(P>0.05).結論 阿託伐他汀鈣聯閤彆嘌醇能更有效改善高脂血癥患者的血脂水平, 同時具有降低尿痠作用, 而聯閤小劑量彆嘌醇即可達到良好治療效果.
목적 관찰아탁벌타정개연합불동제량별표순대고지혈증환자혈뇨산(UA)급혈지수평적영향.방법 90례고지혈증반고뇨산혈증환자수궤분위삼조:A조(상규제량별표순치료)、B조(소제량별표순+아탁벌타정치료)급C조(상규제량별표순+아탁벌타정치료), 각30례.치료4주후비교삼조환자치료전후적혈뇨산화혈지적변화급불량반응.결과 치료4주후삼조혈뇨산균현저하강, 기중B、C조균비A조하강경명현, 차이유통계학의의(P<0.05).A조총담고순(TC)、감유삼지(TG)、저밀도지단백담고순(LDL-C)경도하강, 여치료전비교, 차이유통계학의의(P<0.05), B、C조TC、TG、LDL-C현저하강, 여치료전비교, 차이유통계학의의(P<0.05).치료4주후, B조여C조혈지급혈뇨산지표상비교, 차이무통계학의의(P>0.05).결론 아탁벌타정개연합별표순능경유효개선고지혈증환자적혈지수평, 동시구유강저뇨산작용, 이연합소제량별표순즉가체도량호치료효과.
Objective To observe influence of atorvastatin combined with different doses of allopurinol on blood uric acid (UA) and blood lipid in hyperlipemia patients.Methods A total of 90 hyperlipemia complicated with hyperuricemia patients were randomly divided into three groups, as group A (conventional dose of allopurinol treatment), group B (small dose of allopurinol + atorvastatin treatment) and group C (conventional dose of allopurinol treatment+ atorvastatin treatment), with 30 cases in each group. Changes of blood uric acid and blood lipid, adverse reactions were compared in the three groups after 4 weeks of treatment.Results All groups had remarkably decreased blood uric acid after 4 weeks of treatment, and groups B and C had much decreased blood uric acid than group A. Their difference had statistical significance (P<0.05). There was statistically significant difference of decreased total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterin (LDL-C) in group A before and after treatment (P<0.05). TC, TG, and LDL-C in groups B and C were obviously decreased after treatment, and their difference had statistical significance (P<0.05). After 4 weeks of treatment, the differences of blood lipid and blood uric acid between groups B and C had no statistical significance (P>0.05).Conclusion Combination of atorvastatin and allopurinol can effectively improve blood lipid and reduce uric acid in hyperlipemia patients. Atorvastatin combined with small dose of allopurinol can provide excellent effect in treatment.
